With a likely trading Nifty range of 23,700-24,700 in the coming week, a Short Strangle strategy could be an effective way to capitalise on expected consolidation
Weekly market outlook, May 5 - 9, 2025: Sensex and Nifty seem favourably placed on charts; however, key momentum oscillators are showing signs of tiring out, hence an interim dip cannot be ruled out.
The NSE Nifty has been struggling below its weekly trend line resistance since October 25, 2024; a breakout can potentially trigger a 6 per cent rally on the index, suggests technical charts.
The initial public offer of electric two-wheeler maker Ather Energy received a 16 per cent subscription on the first day of bidding on Monday. The initial share sale received bids for 86,09,406 shares against 5,33,63,160 shares on offer, according to data available with the NSE. The portion for retail individual investors (RIIs) fetched 63 per cent of subscriptions while the quota for the non-institutional category received 16 per cent of subscriptions. Ather Energy Ltd on Friday said it has mobilised Rs 1,340 crore from anchor investors. The Rs 2,981-crore public issue, with a price band of Rs 304-321 apiece, is available for public subscription from April 28-30. This is the first mainboard public issue of the current financial year 2025-26. The IPO is a combination of a fresh issue of equity shares worth Rs 2,626 crore and an offer-for-sale of 1.1 crore equity shares by promoters and other shareholders. At the upper end of the price band, the IPO size is pegged at Rs 2,981 cro
In the week ahead, Sensex is likely to swing between 78,200 to 80,230 range. Nifty may test 23,400 on the downside, and can potentially rally to 24,800 on the upside; suggests technical charts.
Muthoot Finance share price: In past one year, Muthoot Finance shares have gained 30 per cent as against Sensex's rise of 7 per cent
Nelco share price: The company's board recommended a final dividend of ₹1 per share (10 per cent) (face value of ₹10 each) for the financial year ended March 31, 2025
L&T Technology share price: In its fourth quarter ended March 31, 2025, L&T Tech reported a net profit of ₹310.2 crore, down 9 per cent, as compared to ₹341 crore in the year-ago period
SBI Life share price: In its fourth quarter ended March 31, 2025, SBI Life reported a net profit of ₹813.51 crore as compared to ₹810.8 crore in the year-ago period
Strategy View: With a likely trading range of 23,700-24,600 in the coming week, a Short Strangle strategy could be an effective way to capitalise on expected consolidation
Max India share price: The rights issue will open on Wednesday, May 7, 2025, and close on Thursday, May 22, 2025.
HUL share price: The fast-moving consumer goods (FMCG) giant released its fourth quarter (Q4FY25) results on Thursday, during market hours.
Thyrocare Technologies share price: In Q4, the company's consolidated net profit including exceptional items stood at ₹21.3 crore as compared to ₹17.2 crore a year ago
From down 8%, to up over 3% - the NSE Nifty 50 index seems poised to end higher for the 11th time in the last 13 April months; also a relatively shorter F&O series in terms of trading sessions.
We maintain our positive outlook on the Nifty and recommend continuing with a "buy on dips" approach, citing strong support around the 23,700-23,800 zone
The stock has broken above its 200 DEMA with rising volumes in the last few sessions. The RSI indicator is rising to support the positive momentum
Bharti Hexacom share price: The company along with Bharti Airtel inked agreements with Adani Data Networks Limited, a subsidiary of Adani Enterprises to acquire rights to use 400 MHz of spectrum.
Maharashtra Scooters dividend: In Q4, the company's net profit stood at ₹51.63 crore as compared to ₹0.1 crore a year ago
Waaree Energies share price: The company on Tuesday, after market hours, reported a 34 per cent rise in its net profit for the fourth quarter ended March 31, 2025, to Rs 618.91 crore
Aurobindo Pharma Ltd share price: The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to manufacture and market Dasatinib tablets